Enhanced Multiplex IHC Technology for Precision Oncology

Unlock the potential of cutting-edge technology in oncology research. Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte’s Brightplex® technology, a prominent example of multiplex IHC advancements. This webinar will explore innovative features that elevate the capabilities of this technology, providing a deeper understanding of not only the tumor microenvironment (TME) but also the critical imperative for biomarkers in the context of clinical trials.

Brightplex’s new features incorporate in situ hybridization (ISH) probes for the detection of RNA transcripts alongside traditional multiplex IHC biomarkers. This innovative approach allows the simultaneous detection of several protein expressions and RNA transcripts, facilitating a more complete understanding of the complex molecular dynamics within the TME. The technology is particularly relevant when no or poor antibodies are available for a specific target. Complex cell phenotypes can still be analyzed by combining RNA transcripts and proteins. The featured speakers will showcase how this multimodal technology can significantly enhance biomarker studies.

Join this webinar where experts will walk attendees through the strengths of Veracyte’s Brightplex technology and how their team can help your organization uncover insights on the underlying mechanisms of therapy response and resistance at the individual and cohort level.

Speakers

Jacques Fieschi, PhD, VP of Research & Development, Veracyte

Jacques Fieschi is the Vice President of Research & Development (R&D) at Veracyte. In this role, he leverages his extensive experience in the biotechnology industry to push the boundaries of scientific discovery in immuno-oncology. Previously, he was a key member of the R&D team at HalioDx, an immuno-oncology diagnostics company acquired by Veracyte in August 2021. Earlier in his career, Dr. Fieschi held pivotal positions in R&D at Beckman Coulter, a life sciences manufacturing company, and QIAGEN, a biotechnology research company, where he played a crucial role in advancing cutting-edge technologies. Dr. Fieschi holds a PhD from CNRS (Centre National de la Recherche Scientifique) in France. In addition, he completed post-doctoral work as a research fellow at the French Alternative Energies and Atomic Energy Commission, or CEA, a French public government-funded research organization.

Message Presenter

Aurélie Auguste, PhD, Director, Translational Data Analysis, Veracyte

Aurélie Auguste is Director of Translational Data Analysis at Veracyte. In this role, she oversees a team of experts in bioinformatics and immuno-oncology, and she is at the forefront of cutting-edge research. Prior to this, Dr. Auguste served as a Senior Biomarker Expert at Boehringer Ingelheim, where she led translational studies in oncology and managed the Molecular Histopathology platform. Her earlier contributions include impactful work at Gustave Roussy in translational research in gynecological cancer, following her completion of a PhD at the French National Research Institute for Agriculture, Food and the Environment.

Message Presenter